Modest benefit for advanced biliary tract cancer patients from atezolizumab plus cisplatin/gemcitabine with or without bevacizumab (IMbrave 151 trial).
Another highlight of this year’s ASCO GI Symposium held in San Francisco in January was the update from the IMbrave 151 trial for biliary tract cancer.
IMbrave 151 evaluated the addition of bevacizumab to cisplatin, gemcitabine and atezolizumab in a first line randomized Phase II trial for patients with advanced biliary cancer. Primary endpoint of 6 month progression-free survival was higher in the bevacizumab group (78.2% vs 63.1%) without statistical calculation. Overall survival data is not yet mature.
You can read the abstract and others via the ASCO website: